Kristin Comella

Kristin Comella was formerly the Chief Scientific Officer at U.S. Stem Cell Clinic, a company that offered controversial stem cell treatments. Here are some key points about her:

Background and Role

• Comella served as Chief Scientific Officer at U.S. Stem Cell Clinic for many years, playing a leading role in the company's stem cell treatments and research.1

• She claimed to have over 20 years of experience in stem cell research and had been involved in over 10,000 stem cell procedures at U.S. Stem Cell since 2001.1

Controversies

• Comella's credentials came under scrutiny, as she claimed to have a Ph.D. but it was revealed to be from an unaccredited institution in Panama.2

• She was a key figure in U.S. Stem Cell's legal troubles with the FDA over unapproved stem cell treatments.45

• Comella co-authored a paper on stem cell treatments that was later retracted due to ethical concerns about the study.4

Departure from U.S. Stem Cell

• In September 2019, Comella resigned from her positions as Chief Scientific Officer and board member at U.S. Stem Cell.3

• Her resignation came shortly after a federal court ruled against U.S. Stem Cell in an FDA lawsuit over their stem cell treatments.35

Legacy

Comella was a controversial figure in the stem cell industry. While she positioned herself as an innovator in regenerative medicine, her work and U.S. Stem Cell's practices faced significant legal and ethical challenges from regulators and the scientific community.145